Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats

Thrombosis Research

Volumn 132, Issue 2, 2013, Pages 234-239

  Morishima, Yoshiyuki ^a   Honda, Yuko ^a   Kamisato, Chikako ^a   Shibano, Toshiro ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Anticoagulant; Antithrombotic effect; Bleeding; Dose response; Edoxaban; Margin of safety

Indexed keywords

DALTEPARIN; EDOXABAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK FACTOR; VEIN THROMBOSIS;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ANTICOAGULANT; ANTITHROMBOTIC EFFECT; APTT; BLEEDING; BT2; CI; CONFIDENCE INTERVAL; DOSE REQUIRED FOR 50% INHIBITION OF THROMBUS FORMATION; DOSE REQUIRED TO DOUBLE BLEEDING TIME; DOSE RESPONSE; ED(50); EDOXABAN; FACTOR XA; FXA; INR; INTERNATIONAL NORMALIZATION RATIO; INTRAVENOUS; IV; LMWH; LOW MOLECULAR WEIGHT HEPARIN; MARGIN OF SAFETY; ORAL ADMINISTRATION; PO; PROTHROMBIN TIME; PT; SEM; STANDARD ERROR OF MEAN; UFH; UNFRACTIONATED HEPARIN; VENOUS THROMBOEMBOLISM; VTE;

ANIMALS; ANTICOAGULANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HEPARIN; HIRUDINS; MALE; PYRIDINES; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; THIAZOLES; THROMBOEMBOLISM; WARFARIN;

EID: 84883778197     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.05.020     Document Type: Article

References (15)

1. K.A. Bauer Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa J Thromb Haemost 9 Suppl. 1 2011 12 19
2. K.P. Cabral, and J. Ansell Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation Nat Rev Cardiol 9 2012 385 391
3. T. Furugohri, K. Isobe, Y. Honda, C. Kamisato-Matsumoto, N. Sugiyama, and T. Nagahara DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles J Thromb Haemost 6 2008 1542 1549
4. S. Fujita, T. Fuji, S. Tachibana, M. Nakamura, and M. Kawai Safety and efficacy of edoxaban in patients undergoing hip fracture surgery Pathophysiol Haemost Thromb 37 2010 A95 (P366)
5. T. Fuji, S. Fujita, S. Tachibana, Y. Kawai, Y. Koretsune, and T. Yamashita Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial Blood (ASH Annual Meeting Abstracts) 116 2010 3320
6. T. Fuji, S. Fujita, S. Tachibana, and Y. Kawai Edoxaban versus enoxaparin for the prevention of venous thromboembolism: pooled analysis of venous thromboembolism and bleeding from STARS E-3 and STARS J-V Blood (ASH Annual Meeting Abstracts) 118 2011 208
7. C.T. Ruff, R.P. Giugliano, E.M. Antman, S.E. Crugnale, T. Bocanegra, and M. Mercuri Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation- Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
8. Y. Morishima, Y. Honda, C. Kamisato, N. Tsuji, A. Kita, and N. Edo Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats Thromb Res 130 2012 514 519
9. T. Fukuda, N. Tsuji, Y. Honda, C. Kamisato, Y. Morishima, and T. Shibano Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates Thromb Haemost 106 2011 1062 1068
10. Y. Morishima, K. Tanabe, Y. Terada, T. Hara, and S. Kunitada Antithrombotic and haemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants Thromb Haemost 78 1997 1366 1371
11. S.M. Lavelle, and M.M. Iomhair The reliability of thrombotic tendency measured by intravascular wires in the rat Thromb Res 87 1997 353 357
12. W. Wienen, J.M. Stassen, H. Priepke, U.J. Ries, and N. Hauel Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats Thromb Haemost 98 2007 333 338
13. D.L. Higgins, S.D. Lewis, and J.A. Shafer Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin J Biol Chem 258 1983 9276 9282
14. M.C. Berndt, C. Gregory, G. Dowden, and P.A. Castaldi Thrombin interactions with platelet membrane proteins Ann N Y Acad Sci 485 1986 374 386
15. R.J. Leadley Jr. Coagulation factor Xa inhibition: biological background and rationale Curr Top Med Chem 1 2001 151 159